Topology-enabled long-acting interleukin-2 for advanced low-dose interleukin-2 therapy of autoimmune diseases (IMAGE)

Innovation Press

Topology-enabled long-acting interleukin-2 for advanced low-dose interleukin-2 therapy of autoimmune diseases

Caption

Cyclic and catenated interleukin-2 (IL-2) with intact bioactivity are directly synthesized in living cells.

These variants induce preferential Treg expansion to rebalance immunity.

Extended serum half-life enables weekly low-dose treatment for three autoimmune diseases.

Topology engineering overcomes protein therapeutic limits, offering a platform for next-generation biologics.

Credit

Fang J., Feng R., Tian X., et al. (2026). Topology-enabled long-acting interleukin-2 for advanced low-dose interleukin-2 therapy of autoimmune diseases. The Innovation Life 4:100259.

Usage Restrictions

Credit must be given to the creator.

License

CC BY

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.